4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Biotechnology

Healthcare
$10.46 +1.70%

+$0.16 today

Market cap
$577.85M
Beta
2.76
P/E (TTM)
-4.0
EPS (TTM)
-$2.36
52W Low $3.68High $12.34

Volume 0.68M

Average 0.77M

FDMT Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

4D Molecular Therapeutics, Inc.NASDAQ: FDMT

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue grows, but more slowly than its trailing trend

Q1 FY2026 revenue of $3.05M rose 21664.3% year over year, behind the +383560.9% change in trailing-twelve-month revenue. Sequentially, it fell 96.4% from the prior quarter. Over 3 fiscal years it compounded at +200.9% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 5 analysts of $14.28M (-83.2%) for the fiscal year ending Dec 2026, a slowdown from the +230194.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.05M-96.4% QoQ
Last fiscal yearDec 2025
$85.21M+230194.6% YoY
LTMMar 2026
$88.24M+383560.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21664.3%+24033.3%+2369.0 pp
1 year+230194.6%-83.2%-230277.8 pp
3-year CAGR+200.9%-19.7%-220.5 pp
5-year CAGR+37.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
85.21M USD
Year-over-year change
+230194.6%
4-year CAGR
+47.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How FDMT compares with its peers on the latest reported figures

  • FDMT's LTM Mar 2026 revenue of $88.24M is the highest of the 8 companies compared; the peer median is $14.54M.
  • Its year-over-year change of +383560.9% is the highest of 5, against a peer median of -5.8%.
  • Over three fiscal years its annual growth of +200.9% compares with a peer median of +21.0%.
FDMT Competitors Peer median
Revenue for FDMT and competitors
Company Period LTM YoY 3-year CAGR
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$88.24M +383560.9%+200.9%
RGNXREGENXBIO Inc.LTM Mar 2026$87.82M -44.0%+14.8%
MGTXMeiraGTx Holdings plcLTM Mar 2026$79.76M +131.1%+72.3%
QUREuniQure N.V.LTM Mar 2026$18.09M -10.4%-46.7%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$14.54M —+60.3%
OCGNOcugen, Inc.LTM Mar 2026$4.47M -1.3%+21.0%
SLDBSolid Biosciences Inc.LTM Mar 2026$0 ——
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$0 ——
Peer median (excluding FDMT) $14.54M-5.8%+21.0%

Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.04M3.13M20.72M37K85.21M
Cost of Revenue61.36M80.25M97.1M141.3M7.63M
Gross Profit(43.32M)(77.12M)(76.37M)(141.26M)77.58M
Gross Margin-240.2%-2464.8%-368.5%-381789.2%91.1%
Research & Development61.36M80.25M97.1M141.3M195.7M
Selling, General & Admin28.01M32.91M36.49M46.58M49.06M
Operating Expenses28.01M32.91M36.49M46.58M237.13M
Depreciation & Amortization1.52M2.4M4.2M6.71M7.63M
EBITDA(69.79M)(105.09M)(96.63M)(154.16M)(132.48M)
EBITDA Margin-386.9%-3358.6%-466.3%-416656.8%-155.5%
Operating Income(71.33M)(110.03M)(112.87M)(187.84M)(159.55M)
Operating Margin-395.5%-3516.5%-544.6%-507678.4%-187.2%
Interest Income137K2.57M12.21M27.05M19.48M
Interest Expense00000
Other Income / Expenses16K2.54M12.03M26.97M19.44M
Income Before Tax(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Pre-Tax Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
Income Tax Expense00000
Net Income(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Net Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
EPS (Basic)(2.46)(3.12)(2.58)(2.98)(2.42)
EPS (Diluted)(2.46)(3.12)(2.58)(2.98)(2.42)
Weighted Avg Shares27.73M32.35M39.13M53.94M57.93M
Weighted Avg Shares (Diluted)27.73M32.35M39.13M53.94M57.93M

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Intrinsic Alpha fair value

Locked

Current Price

$10.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.